These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24944370)

  • 1. Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
    Grossberg GT
    Curr Ther Res Clin Exp; 2003 Apr; 64(4):216-35. PubMed ID: 24944370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
    Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
    Lane RM; Potkin SG; Enz A
    Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
    Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ABC of Alzheimer's disease: behavioral symptoms and their treatment.
    Grossberg GT
    Int Psychogeriatr; 2002; 14 Suppl 1():27-49. PubMed ID: 12636179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
    Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
    Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
    Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J
    Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
    Farlow M
    Int Psychogeriatr; 2002; 14 Suppl 1():93-126. PubMed ID: 12636182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.